For his commitment to building a thriving bioscience community in Tempe and his work on behalf of life science innovators across our state, The Honorable Mark Mitchell, Mayor of the City of Tempe, Arizona is being honored with the 2017 AZBio Public Service Award.

Presented by  Debra Hanna, PhD - Executive Director, Critical Path to TB Regimens (CPTR), Critical Path Institute, and Richard Liwski – Program Director, Data Collaboration Center, Critical Path Institute

Mayor W. J. “Jim” Lane served for four years on the Scottsdale City Council beginning in June 2004, and began his first term as Mayor in January 2009. He was re-elected to the Mayor’s Office in 2012 and began his second term in January of 2013.  Mayor Lane serves as a member of the Arizona Bioscience Roadmap Steering Committee and has been a lead driver in the development of Scottsdale’s Cure Corridor. 

Recorded Live at the AZBio Expo on June 19, 2014 in Scottsdale, Arizona

The maxim “If you need to get something done, ask a busy person” often has been attributed to Benjamin Franklin. The 2017 Arizona Bioscience Pioneer honoree, Marvin J. Slepian, MD, is someone Franklin would have recognized as a kindred spirit. Dr. Slepian is a cardiologist, inventor, entrepreneur, educator, innovator and more. At the University of Arizona, he serves as professor of medicine, professor and associate department head of biomedical engineering, professor of material sciences and engineering, professor of medical imaging, McGuire Scholar in the UA Eller College of Management and member of the UA Sarver Heart Center. Dr. Slepian also is the founder and director of the newly created Arizona Center for Accelerated Biomedical Innovation (ACABI) – a “creativity engine” focused on novel solution development for unmet medical needs.

Michael Kozlowski OD, PHD,  Chief Science Officer

Kalos Therapeutics, Inc dedicated to treating patients not just their  diseases. Kalos is a peptide therapeutic company treating virulent cancers and the related comorbidities. The Kalos solution focuses in putting tumor cells into a prolonged non dividing state, also treating the ascites and edema that lead to pain and death. Kalos drugs engage known pathway receptors in the MAPK pathway and it does so more efficiently without the side effects associated with chemotherapeutic compounds. As confirmed in an Investigator IND our clinical effects of increased natriuresis and diuresis will treat the related comorbidities of cancer reducing ascites, and edema, as well as shrinking the tumor.

Clinical Trialsin Arizona - Engaging Patients in the Process (Panel)

• Greg Vigdor - Moderator (President & CEO, Arizona Hospital and Healthcare Association)
• Brian Browne (Director - Education & Outreach, Banner Research)
• Barbara Kavanaugh (Arizona Myeloma Network )
• Marcia K. Horn, JD (International Cancer Advocacy Network)

Presented by Dirk Karsten Beth, Arivis